Comparison of PFS between maintenance strategies for transplant-eligible patients. “b” indicates sensitivity analysis using data from the CASSIOPEIA trial focusing on patients who did not have Dara as induction therapy. Dara, daratumumab; Ixa, ixazomib; Len, lenalidomide.